Daniel Gilbert

Washington, D.C.

Reporter covering the business of medicine

Education: University of Chicago, BA in International Studies

Daniel Gilbert joined The Washington Post in 2022 and writes about the business of medicine. He previously spent seven years as an investigative reporter for the Seattle Times, and before that covered business and energy for the Wall Street Journal in Houston. As a staff writer for the Bristol Herald Courier in Bristol, Va., his reporting on Virginia’s mismanagement of natural-gas royalties received the 2010 Pulitzer Prize for Public Service.
Latest from Daniel Gilbert

The top 3 insulin makers recently announced price cuts. Here’s what to know

The drugmaker says the move will make the diabetes medication more accessible, especially for those who have trouble navigating the “complex health care system.”

March 17, 2023

An Adderall shortage hasn’t let up. Here’s why.

Telehealth made access to ADHD drugs easier for many. But a shortage has put the spotlight on virtual prescribing and supply chain issues.

March 14, 2023

Novo Nordisk becomes latest producer to slash insulin prices

Novo Nordisk said it would cut list prices of several of its insulin products by as much as 75 percent, the latest major producer to reduce prices following public pressure to curb the cost of diabetes treatment.

March 14, 2023

Pfizer seeks another ‘moonshot’ with $43 billion cancer deal

Pfizer said it will buy Seagen, a major push into cancer-fighting drugs as Pfizer remakes itself with financial windfall netted from its covid treatments.

March 13, 2023

The race to beat Elon Musk to put chips in people’s brains

Though their approaches vary, innovative companies like Paradromics and Synchron are trying to hack the brain’s instructions to the body and transmit them directly to an electronic device — enabling, for example, a person to move a cursor by thinking about it.

March 3, 2023

Eli Lilly to cut insulin prices by 70 percent

The price of the medication has become a political issue as diabetics have struggled to afford the lifesaving drug

March 1, 2023

How a Cambodian monkey-smuggling ring could worsen U.S. lab shortages

Several major companies are warning of supply constraints, delays and higher prices in the wake of a federal investigation.

March 1, 2023

Investigation spotlights rise of for-profit ethics boards in research

A federal investigation calls for more oversight of institutional review boards, designed to protect the welfare of people participating in research.

February 16, 2023

Official end of covid emergency injects uncertainty into telehealth

The federal public health emergency declaration waived the requirement for health-care providers to meet patients in person before prescribing controlled substances.

January 31, 2023

CBD not shown to be safe enough for use in food or supplements, FDA says

Despite hopes of CBD backers, the FDA is not greenlighting the product.

January 26, 2023